March 11, 2021 Clinical Research/Diagn. Microscopy PR/Corporate

Roche’s awarded WHO prequalification for the HIV and HCV diagnostic tests on the cobas 6800/8800 Systems

For patients living in areas with limited healthcare resources, WHO prequalification ensures access to the highest quality diagnostics Access to broader reliable diagnostic solutions helps healthcare communities working to expedite and increase disease elimination programs Roche’s Global Access Program provides innovative diagnostic solutions improving disease and patient management for those most in need Basel, 11... Read more

March 9, 2021 Clinical Research/Diagn. Licensing, IP, and Legal

Agilent Completes CE-IVD Registration of qRT-PCR In Vitro Diagnostic Kit for SARS-CoV-2 RNA Detection

Kit expands Agilent’s product portfolio aimed at COVID-19 detection SANTA CLARA, Calif., March 09, 2021  Agilent Technologies Inc. (NYSE: A) today announced the launch of a real-time reverse transcription (qRT) PCR-based diagnostic kit for the detection of SARS-CoV-2 RNA. The CE-IVD mark is in accordance with the European Union In Vitro Diagnostic Directive 98/79/EC and... Read more

March 3, 2021 Clinical Research/Diagn. Product Launch

QIAGEN launches QIAsphere cloud-based connectivity solution to enhance QIAstat-Dx capabilities in digital diagnostics

Hilden, Germany, and Germantown, Maryland, March 3, 2021 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) has launched its QIAsphere cloud-based platform that will allow labs and QIAstat-Dx users to monitor tests and instrument status remotely 24 hours a day, 7 days a week. QIAsphere sets new standards for syndromic testing digital health, providing users with... Read more

March 2, 2021 Clinical Research/Diagn. M&A, Partnerships

Agilent to Acquire Resolution Bioscience, Strengthening Leadership Position in Cancer Diagnostics

SANTA CLARA, Calif., March 02, 2021  Highlights: Resolution Bioscience is a fast-growing, innovative leader in next-generation sequencing (NGS)-based oncology solutions. Combination brings together Resolution Bioscience’s noninvasive liquid biopsy platform that improves cancer diagnostics with Agilent’s leadership in tissue-based companion diagnostics and global commercial and regulatory scale. Furthers Agilent’s participation in fast-growing NGS technologies for precision... Read more

March 2, 2021 Clinical Research/Diagn. Product Launch

QIAGEN launches QIAcube Connect MDx platform for automated sample processing in diagnostic labs

Germantown, Maryland, and Hilden, Germany, March 02, 2021 – QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the global launch of the QIAcube Connect MDx, a flexible platform for automated sample processing that will now be available to molecular diagnostic laboratories in the U.S. and Canada, the European Union and other markets worldwide.... Read more

February 24, 2021 Clinical Research/Diagn. Lab Top-10 Life Science Tools M&A, Partnerships

QIAGEN and INOVIO expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO’s VGX-3100 for advanced cervical dysplasia

PLYMOUTH MEETING, PA., USA, and GERMANTOWN, MD., USA, and HILDEN, Germany, February 24, 2021 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO Pharmaceuticals (NASDAQ: INO) today announced an extension of their partnership with a new master collaboration agreement to develop liquid biopsy-based companion* diagnostic products based on next-generation sequencing (NGS) technology to complement... Read more

February 23, 2021 Clinical Research/Diagn. M&A, Partnerships

Bio-Techne and Luminary Therapeutics Sign License Agreement for Use of Bio-Techne’s TcBuster for the Development of Luminary’s CAR-T Cell Therapies

FEBRUARY 23, 2021 MINNEAPOLIS, Feb. 23, 2021 /PRNewswire/ — Bio-Techne Corporation (NASDAQ: TECH) today announced the signing of a license agreement with Luminary Therapeutics for the use of TcBuster™ for the manufacturing of gene-modified cell therapies. TcBuster is Bio-Techne’s proprietary non-viral transposon-based gene delivery system used to advance cell therapy manufacturing.   Under the terms of this agreement,... Read more

February 23, 2021 Clinical Research/Diagn. Lab Top-10 Liq. Handling & Robotics

PerkinElmer Changes COVID-19 Rapid Testing Landscape with Highly Sensitive Point of Care Antigen Test for Mass Screening

Company expands portfolio of SARS-CoV-2 testing solutions with rapid antigen test benchmarked against gold standard RT-PCR WALTHAM, Mass.–(BUSINESS WIRE)–Feb. 23, 2021– PerkinElmer, Inc. (NYSE: PKI) today announced the launch of the PerkinElmer® COVID-19 Antigen Test for the qualitative detection of SARS-CoV-2 nucleocapsid protein antigen in nasal (NS) or nasopharyngeal (NP) swab specimens. The lateral flow... Read more

February 23, 2021 Atomic Spectroscopy Clinical Research/Diagn. Lab Top-10

Thermo Fisher Scientific Announces Oncomine Clinical Research Grant 2021 Call for Submissions

Thermo Fisher Scientific Announces Oncomine Clinical Research Grant 2021 Call for Submissions CARLSBAD, Calif., Feb. 23, 2021 /PRNewswire/ — Thermo Fisher Scientific has opened a call for submissions for its Oncomine Clinical Research Grant program to support clinical research. The program aims to assist educational and independent research projects that exhibit excellence in molecular profiling... Read more

February 22, 2021 Clinical Research/Diagn. Licensing, IP, and Legal

Agilent PD-L1 IHC 22C3 pharmDx Receives Expanded FDA Approval in Non-small Cell Lung Cancer (NSCLC)

Companion diagnostic can help guide treatment decisions in cases of NSCLC SANTA CLARA, Calif., February 22, 2021  Agilent Technologies Inc. (NYSE: A) today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s PD-L1 IHC 22C3 pharmDx assay for expanded use in patients with non-small cell lung cancer (NSCLC). PD-L1 IHC 22C3... Read more